Evaluation of the clinical utility, efficacy and safety of a novel medical device for the treatment of foot ulcers: Rationale and design of the carbothera trial


BACKGROUND: Foot ulceration usually precedes more serious foot complications such as infection, gangrene or amputation. The risk of developing foot ulcers has been estimated to be higher in individuals with peripheral arterial disease, diabetes and kidney disease. OBJECTIVE: To evaluate the healing potential of CO2-enriched water in patients with foot ulceration. METHODS: This is a multicentered, placebo controlled and randomized clinical trial. Patients will have at least 1 distal extremity ulcer and will be randomized to receive a treatment with bath therapy at 37°C containing either 1,000-1200 ppm CO2-enriched tap water (the intervention), or non-carbonated tap water (the control group). The treatment will be carried out 3 times/week for 15 minutes per session for 4 months for a total of 48 treatments. At baseline and at the end of every treatment month, wound assessment, measurement of limb oxygenation, ankle brachial pressures as well as McGill pain questionnaire will be carried out. Blood will also be collected at baseline and at the end of every month of the treatment period (for a total of 5 collections) for the measurement of different biomarkers. BASELINE DATA: At baseline all 14 participants have at least one distal extremity ulcer and 93% (13/14) are diabetic. Although 6 of the participants have peripheral arterial disease (left and/or right limb) as evidenced by an ankle brachial index (ABI) ≤0.9, another 5 exhibited non-compressible ankle arteries and 3 participants with left and right ABI ≥ 0.9. Mean age of participants is 60.2 ± 1.7 and 64% (9/14) of the participants are undergoing hemodialysis for ESRD and 29% (4/14) are below knee amputees. CONCLUSIONS: The proposed clinical study will evaluate the therapeutic potential, safety and efficacy of CO2-enriched water (produced by the Carbothera device) on treating foot ulcers.

Key Words: Foot ulcers; Diabetes; Peripheral arterial disease; Hemodialysis; Foot bathing, CO2-enriched water

The risk of developing foot ulceration has been estimated to be 25% higher in individuals with diabetes (1), representing a huge economic burden on health care costs (2). Bacterial infection, tissue ischemia, continuing trauma, and poor management cause diabetic foot ulcers to heal slowly and transform into chronic wounds (3). Critical limb ischemia (CLI) is a severe form of peripheral arterial disease (PAD). PAD, commonly affecting tibial and peroneal arteries of the calf, contributes to the development of foot ulcers in up to 50% of cases. Among other factors, the vasoconstriction secondary to a decrease in endothelium-derived vasodilators plays a central role in the pathophysiology of foot ulcers (4). The aims of management in patients with CLI are to relieve ischemic pain, heal ulcers, prevent limb loss, improve function and quality of life and prolong survival (5). Dialysis is a risk factor for foot complications in patients with diabetes and chronic kidney disease (CKD) (6). Indeed, patients with diabetes and CKD receiving dialysis have a 5-fold higher prevalence of foot ulceration as compared to pre dialysis diabetic patients (7). It has also been observed that the prevalence of other lower limb complications (amputation, PAD, prior ulcer and neuropathy) was approximately 2-fold higher in patients receiving dialysis. Foot ulceration usually precedes more serious foot complications such as severe infection, gangrene or amputation. In a retrospective study involving 90 patients with diabetes who started dialysis, it was found that the cumulative incidence of foot ulceration and amputation increased before the initiation of dialysis and then was highest in the subsequent 2 years (8).

During hemodialysis there is a reduction in skin microcirculation and tissue oxygenation that may contribute to the development of ulceration in patients with diabetes (9). In this regard, some studies have shown an improvement in peripheral blood flow in patients with different stages of PAD in response to Carbothera treatment (10-15). It is known that CO2 causes vasoconstriction and thus immersing the extremities into carbonated water will increase skin blood flow, given that CO2 can permeate through the skin (15). The Carbothera device has also been examined in diabetic foot ulcers (16,17). However, in view of the limitations of case studies, there is a need for a well-designed clinical trial to determine the efficacy of CO2-enriched water (1000-1200 ppm) produced by the Carbothera device to relieve foot ulcers. Moreover, despite the fact that multiple treatments have been studied and used for ulcer healing (18), only 24-50% of all ulcers will heal after 12 weeks to 6 months of standard treatment (19,20). The proposed clinical trial will, therefore, evaluate the therapeutic potential of CO2-enriched water in patients with foot ulceration. Accordingly, this study will test the hypothesis that CO2-enriched water bath treatment generated by the Carbothera device will reduce foot ulcer size. The general objective of the study is to evaluate determine peripheral blood flow in patients to evaluate the efficacy of CO2-enriched water on treating foot ulcers in patients. The specific objectives of the study are to:

- Determine peripheral blood flow in patients following CO2-enriched water treatment.
- Determine ulcer size and rate in response to CO2-enriched water treatment.
- Investigate limb oxygenation in response to CO2-enriched water treatment.
- Determine the effect of CO2-enriched water treatment on biomarkers of angiogenesis, inflammation, as well as lipid profile, fasting blood glucose and HbA1c.

1St Boniface Hospital, Asper Clinical Research Institute and 1Department of Physiology and Pathophysiology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada, 2Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada, 3Department of Pharmacology and Therapeutics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada, 4Mitsubishi Rayon America Inc., New York, USA, 5Mitsubishi Chemical Holdings, Tokyo, Japan

Correspondence: Dr. Paramjit S. Tappia, Asper Clinical Research Institute, CR3129-369 Tache Avenue, Winnipeg, Manitoba, Canada R2H 2A6, Telephone 204-258-1230, email ptappia@bmc.ca

Received: August 12, 2016, Accepted: August 16, 2016, Published: August 18, 2016

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com
METHODS

Study Design

This is a multicentered, placebo controlled and randomized clinical trial. Study participants will be patients with foot ulceration. The inclusion and exclusion criteria are shown in Table 1.

TABLE 1

Inclusion and exclusion criteria

Inclusion:
1. Male and female participants ≥ 18 years of age with at least one distal extremity ulcer (arterial ischemic ulcer).
2. No acute medical illness and on conventional medical management prior to Carbothera.
3. Willingness and ability to provide written informed consent

Exclusion:
1. DVT or PE within the past 12 months.
2. Subjects with known active cancer, HIV, hepatitis B virus, hepatitis C virus, human transmissible spongiform encephalopathy, Treponema pallidum.
3. Subjects who are deemed to have an infection of the distal extremity ulcer.
4. Pregnant women.
5. Unstable angina.
6. Acute MI within 1 month.
7. Stroke within 1 month.
8. Patient scheduled for revascularization during the 4-month intervention period.

Patients will be randomized to receive a foot bath treatment with either CO2-enriched tap water (1,000-1,200 ppm CO2 (the treatment group), or non CO2-enriched tap water (the control group). The Carbothera ™ is a device used to generate CO2-enriched water (Figure 1).

Figure 1) Carbothera device for foot bathing

The use of this device does not involve contact with the patient. A major component of the device is the gas-permeable hollow fibre (GPH ™) membrane developed by Mitsubishi Rayon Cleansui; Tokyo, Japan. The membrane is composed of a non-porous ultra-thin film with gas-selective permeability that is sandwiched between two porous layers. The GPH™ membrane conveniently produces large quantities of CO2-enriched water (Figure 2).

Figure 2) The unique Carbothera membrane system for producing CO2 in a rapid and inexpensive manner. Panel A shows the structure of the GPHTM membrane developed by Mitsubishi Rayon Cleansui; Panel B shows CO2-enriched water production with the GPHTM membrane

The middle layer of the GPH ™ membrane allows CO2 to pass through, but is impermeable to water. CO2 on the high-pressure side diffuses through the molecular structure of the thin film and dissolves into the water on the low-pressure side. A large number of GPH ™ membranes can be bundled together into a module, which can be used to produce a large amount of water containing a high concentration of dissolved CO2. The bath therapy will be carried out at 37°C; 3 times/week, for 15 minute sessions for a total of 4 months. Blood (approximately 20 ml) will also be collected at baseline and at the end of every month of the treatment period (for a total of 5 collections) for the measurement of the different biomarkers.

Participant Selection, Recruitment and Informed Consent

Participants will be screened for eligibility and then approached for written informed consent before enrolment into the study. Patient demographics (diabetes, PAD, hemodialysis) will be recorded at screening. Participants will be given both written and verbal information describing the nature of the study. Sufficient time will be allowed for participants to provide their consent. The procedures for conducting informed consent will be documented in the study records and a copy of the signed consent will be given to the participants enrolled in the study. Information on participant eligibility will also be obtained from the individual's medical history.

Foot Bathing

Participants will undergo foot bathing with CO2-enriched tap water (37°C; CO2 concentration of 1000-1200 ppm) or a non-CO2-enriched tap water (37°C) with an immersion time of 15 minutes, 3 times per week for 4 months for a total of 48 treatments. Participants will be rested on a chair for 15 min before foot bathing. The primary and secondary outcome measures are shown in Table 2.

TABLE 2

Primary and secondary outcome measurements

Primary outcome measures:
1. Ulcer area (length x width).
2. Ulcer volume (length x width x depth).
4. Ulceration rate.
5. Ankle-brachial index/Blood flow by Doppler.

Secondary outcome measures:
1. Degree of rest pain.
2. Limb oxygenation by a non-invasive near infra-red spectroscopy.
3. Angiogenesis marker: vascular endothelial growth factor (VEGF).
4. Inflammatory markers: TNFα, IL-6 and C-reactive protein.
5. Markers of glucose handling: HbA1c and fasting blood glucose.
7. Use of bespoke footwear.
8. Ability to walk barefoot at home.
10. Use of antibiotics indicated for the ulcer treatment.

In order to achieve these, the following procedures will be conducted 5 times: at baseline, 1, 2, 3 and 4 months.

Measurement of ulcer size

The Silhouette Mobile camera (ARANZ Medical, Christchurch, New Zealand) will be used to measure ulcer area, volume and depth. This device is a portable handheld computer with an integrated high-resolution digital camera and an embedded laser light. The device has been shown to be accurate to within 2% of surface area on wound models and has demonstrated intra- and inter-user variability of only 2–5% in clinical use (21).

Ankle/Brachial Index (ABI)/Blood flow

A continuous wave, hand held Doppler machine will be used with a blood pressure cuff and a conventional sphygmomanometer to measure the systolic pressure in both the posterior tibial (PT) and dorsalis pedis (DP) arteries. If no PT or DP arterial signals are found, the anterior tibial and/or peroneal arterial pressure will be recorded. The ankle systolic pressure and brachial systolic blood pressure will be calculated as ankle systolic pressure/brachial systolic pressure (ABI). The subject will be asked to rest supine for 10 minutes before ABI measurements. Brachial systolic and diastolic pressures as well as heart rate will also be measured. The ABI has a high level of sensitivity.
and specificity for diagnosing PAD (22). In the event that PT/DP are non-compressible, toe pressures by photoplethysmographic (PPG) technique will be measured.

**Limb oxygenation**

Changes in limb blood volume and oxygenation will be recorded using noninvasive near-infrared spectroscopy (NIRS) (23-26). NIRS measures the percentage of hemoglobin oxygen saturation in the microcirculation of tissue up to 3 cm below the skin (24).

**Biochemical measurements**

Blood samples from participants will be analyzed for C-reactive protein, glucose, total cholesterol, triglycerides, high density lipoprotein (HDL)-cholesterol and low density lipoprotein (LDL)-cholesterol levels using standard methods by Laboratory Services at St. Boniface Hospital operated by Diagnostic Services of Manitoba. TNF-α, IL-6 and VEGF will be measured by ELISA method in the Albrechtsen Research Centre at St Boniface Hospital in Winnipeg, Canada as described elsewhere (27).

**Questionnaires**

The short form McGill Pain Questionnaire (28) will be used to assess the degree of rest pain. A questionnaire will also be used to determine the use of other therapies. A patient self-report for the following will be conducted: use of bespoke footwear or insoles and ability to walk barefoot at home. Use of antibiotics indicated for the ulcer treatment during the period of the trial will also be recorded in the questionnaire. Responses to these questions will be recorded as Yes (with frequency noted) or No at baseline and at the end of 2 and 4 months of treatment (7).

**Safety/Rescue Medication**

Since this is not a drug study, rescue medication is not warranted. No adverse effects are expected based upon literature and prior experience. Should any participant experience adverse effects as a consequence of their participation in the study, they will be excluded from the study and receive routine medical care. However, any adverse events, as identified by the WHO scale, will be followed up. Research staff will record final outcome and resolution date of the event wherever possible. All serious adverse events (representing a significant health hazard to the participant) will be reviewed by the monitor and reported in an expedited manner to Health Canada, the Research Review Committee of St. Boniface Hospital and the University of Manitoba Research Ethics Board.

**Premature Withdrawal/Discontinuation Criteria**

Participants are entitled to withdraw from study at any time for any reason. In addition, the study will be halted at any time should the data safety and monitoring committee deem it harmful to the participants to continue with the trial. The clinical investigator may withdraw any participant from the study at any time for medical reasons, or if the participant is consistently and continually non-compliant with the study protocol.

**Statistical Analysis**

Previous analyses exploring the effectiveness of CO₂-enriched water as compared to noncarbonated water for improving limb function following continuous treatment have shown large positive effects in favor of CO₂-enriched water for both changes in microcirculation; difference = 2.20 standard deviations (12) and ulcer size (16); Difference = 0.70 standard deviations. A final sample size of 40 individuals will allow for the detection of a standard deviation difference of 0.90 for in ulcer area/volume, blood flow, and ankle-brachial index as measured by Doppler at 80% power and 5% alpha. This sample size will also allow for large absolute differences (35%) to be detected in the formation of new ulcers, and the ulceration rate at 80% power and 5% alpha.

A repeated measures analysis of variance (ANOVA) will be utilized to discriminate differences in the continuous outcome variables within the experimental group across the sampling time period (baseline, 1, 2, 3 and 4 months). Where significant within-subject differences are found, a Newman-Kuels post-hoc test will be used to compare specific mean scores across the repeated measures time factor. Event rate differences for all dichotomous variables will be analyzed using Kaplan Meier Survival Curves with a follow-up period of four months. For all statistical analyses, the significance level will be set at P < 0.05.

**RESULTS**

**Baseline data**

Some of the baseline characteristics of the 14 participants that have, to date, been compliant with the baseline visit, are presented in Table 3.

**TABLE 3**

<table>
<thead>
<tr>
<th>Participants (n)</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60.2 ± 1.7</td>
</tr>
<tr>
<td>Sex (%) M/F</td>
<td>64 M (9); 36 F (5)</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>93 (13)</td>
</tr>
<tr>
<td>Hemodialysis (%)</td>
<td>64 (9)</td>
</tr>
<tr>
<td>Fasting Blood Glucose (mM)</td>
<td>10.30 ± 1.54</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>8.81 ± 0.55</td>
</tr>
<tr>
<td>Cholesterol (mM)</td>
<td>4.02 ± 0.27</td>
</tr>
<tr>
<td>Triglycerides (mM)</td>
<td>1.90 ± 0.46</td>
</tr>
<tr>
<td>HDL-cholesterol (mM)</td>
<td>1.04 ± 0.12</td>
</tr>
<tr>
<td>LDL-cholesterol (mM)</td>
<td>2.10 ± 0.22</td>
</tr>
<tr>
<td>Total cholesterol/HDL-cholesterol ratio</td>
<td>3.95 ± 0.36</td>
</tr>
<tr>
<td>LDL-cholesterol/HDL-cholesterol ratio</td>
<td>2.21 ± 0.31</td>
</tr>
<tr>
<td>C-reactive Protein (mg/L)</td>
<td>15.05 ± 4.25</td>
</tr>
</tbody>
</table>

Values are means ± S.E. of 13-14 independent measurements. Reference range for fasting glucose, 3.6-6.0 mM; HbA1c, 4.0-6.0 %; cholesterol, < 5.2 mM; triglycerides, < 1.7 mM; LDL-cholesterol > 1.0 mM; LDL-cholesterol < 3.4 mM; total cholesterol/HDL-cholesterol < 4.5 mM; LDL-cholesterol, < 3.5 mM; C-reactive protein, < 5.0 mg/L.

The population has an average age of 60.2 years and there are 9 males and 5 female participants. For 1 patient we were unable to draw a baseline blood sample. Ninety three percent (13/14) are diabetic, as evidenced by an approximate 2-fold elevation of the mean fasting blood glucose (reference values 3.6-6.0 mM) and an approximate 1.5-fold increase in the mean values for HbA1c (reference value 4.0-6.0 %). Sixty four percent (9/14) of the participants are undergoing dialysis for ESRD. Of the 13 baseline blood analysis, 2 participants have elevated total cholesterol levels (reference <5.2 mM), 11 (85%) participants have increased triglycerides, 3 (23%) participants have increased total cholesterol/HDL-cholesterol levels (reference <4.5 mM) and 2 (15%) have elevated LDL-cholesterol/HDL-cholesterol levels (reference <3.5

**Evaluation of the clinical utility, efficacy and safety**

Confidentiality of Data

All information collected for the purpose of the study will be kept in a locked and secured area. All information collected and sent for statistical analysis will only have the participant’s initials and study number. Only the research personnel will be able to link the study identifiers and the participant’s name. All identifiers will be treated in confidence and in accordance with the Personal Health Information Act of Manitoba. Study records will be retained for 25 years. For the purpose of trial-related monitoring/auditing, the University of Manitoba Research Ethics Board and the St. Boniface Hospital Research Review Committee will have access to source data and study records.

**Ethics Approval**

Written approvals from the Research Ethics Board at the University of Manitoba and St. Boniface Hospital Research Review Committee have been obtained prior to implementation of the study and enrollment of any participants. The tenets of Good Clinical Practice will also be followed in the conduct of this study.

**Essential Study Documents and Study Access**

The Principal Investigator accepts responsibility for the overall conduct of the study and for the documents that are essential for the conduct of the study. Any documents which reveal the identity of the patient (such as the consent form) will be stored in the Principal Investigator’s office at St. Boniface Hospital in a locked cabinet. Direct access to all documents associated with this study will be permitted in the case of auditing by the University of Manitoba Research Ethics Board and St. Boniface Hospital. Archiving will be done as per the standard regulatory and institutional requirements.
mM. Eight (62%) participants have low HDL-cholesterol levels (reference >1.0 mM). It should be noted that 85% (11/13) of the participants have elevated Creative protein levels (normal range <5 mg/L).

Table 4 shows some of the baseline limb characteristics of the participants. It can be seen that 29% (4/14) patients are below knee amputees. All patients have at least one distal extremity ulcer. It should be noted that the mean value for O₂ saturation at the site of the wound is around 40%.

**TABLE 4**

Baseline limb characteristics of patients enrolled into the Carbothera Study

| Amputees (n) | 36 % (5) |
| BKA (n)      | 4        |
| Toe (n)      | 1        |
| Number of wounds | 20 |
| % O₂ saturation at site of ulcer (n) | 40.89 ± 4.81 (20) |
| Right Ankle Brachial Index | 0.87 ± 0.09 (8) |
| Left Ankle Brachial Index | 0.90 ± 0.06 (9) |
| Right side non compressibility (n) | 2 |
| Left side non compressibility (n) | 5 |

Values are means S.E. of indicated independent measurements. BKA, below knee amputation.

Although 6 of the participants have peripheral arterial disease (left and/or right limb) as evidenced by an ankle brachial index (ABI) <0.9, specifically, 29% (4/14) of the participants have left side ABI mean value of 0.79, and 36% (5/14) have a right side ABI mean value of 0.70, which corresponds with mild to moderate obstruction of peripheral arteries in the limbs. It is pointed out that in 3 of the participants both right side and left side ABI is >1.0, indicating no significant narrowing or blockage of peripheral blood flow. An ABI in either right and left side or both was not attainable in 5 participants due to non-compressibility of the peripheral arteries.

**DISCUSSION**

Many interventions have been proven with the objective of improving the healing process of diabetic and ischemic foot ulcers. Amongst others, the treatment includes: off-loading, wound debridement, control of gangrene or sepsis, antibiotic therapy and negative-pressure wound therapy. Nevertheless, these therapeutic measures can prosper only in the presence of adequate arterial perfusion (29). The Carbothera foot care study will generate data on the safety, tolerability, vascular efficacy and capacity to heal ulcerated foot lesions. It will provide data on the biochemical parameters that may be involved in the healing process. It will determine, for the first time, the effects of the Carbothera CO₂ bath on primary events such as ulcer area (length x width), ulcer volume, (length x width x depth), the formation of new ulcers, ulceration rate and ankle-brachial index/Blood flow by Doppler (as shown in Table 2) as well as secondary endpoints such as the degree of rest pain, limb oxygenation (O₂ saturation), measurement of angiogenesis marker, inflammatory markers, fasting blood glucose, HbA1c, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, use of bespoke footwear, ability to walk barefoot at home, incidence of amputation and use of antibiotics indicated for the ulcer treatment, in patients with ulcerated lesions (as shown in Table 2). The interest about CO₂ as potential healing compound is based on its capacity as vasodilator of blood vessels and its capacity on improving the tissue perfusion in areas under perfused (10). The development by Mitsubishi Rayon Cleansui, Tokyo, Japan, of a gas compound is based on its capacity as vasodilator of blood vessels and its capacity as vasoradilator of blood vessels.

**REFERENCES**